News
-
-
-
PRESS RELEASE
Kedrion: at ESID 2026, experts call for earlier diagnosis and greater awareness as Secondary Immunodeficiencies continue to rise
Experts at ESID 2026 emphasize the need for earlier diagnosis and increased awareness of Secondary Immunodeficiencies, highlighting challenges and calls for improved patient outcomes -
-
-
PRESS RELEASE
European Medicines Agency (EMA) grants Orphan Drug Designation to Kedrion's plasma-derived treatment for Congenital Aceruloplasminemia, a rare genetic disorder of iron metabolism
Kedrion's plasma-derived treatment for Congenital Aceruloplasminemia granted Orphan Drug Designation by EMA, highlighting commitment to rare disease innovation -
-
-
